Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy

Christopher J. Franzese, Kevin P. Bliden, Martin G. Gesheff, Shachi Pandya, Kirk E. Guyer, Anand Singla, Udaya S. Tantry, Peter P. Toth, Paul A. Gurbel

Research output: Contribution to journalArticle

Abstract

Fish oil supplementation (FOS) is known to have cardiovascular benefits. However, the effects of FOS on thrombosis are incompletely understood. We sought to determine if the use of FOS is associated with lower indices of atherothrombotic risk in patients with suspected coronary artery disease (sCAD). This is a subgroup analysis of consecutive patients with sCAD (n = 600) enrolled in the Multi-Analyte, Thrombogenic, and Genetic Markers of Atherosclerosis study. Patients on FOS were compared with patients not on FOS. Lipid profile was determined by vertical density gradient ultracentrifugation (n = 520), eicosapentaenoic acid + docosahexaenoic acid was measured by gas chromatography (n = 437), and AtherOx testing was performed by immunoassay (n = 343). Thromboelastography (n = 419), ADP- and collagen-induced platelet aggregation (n = 137), and urinary 11-dehydrothromboxane B2 levels (n = 259) were performed immediately before elective coronary angiography. In the total population, FOS was associated with higher eicosapentaenoic acid + docosahexaenoic acid content (p 2 levels regardless of lipid-lowering therapy (p

Original languageEnglish (US)
Pages (from-to)1204-1211
Number of pages8
JournalThe American Journal of Cardiology
Volume115
Issue number9
DOIs
StatePublished - May 1 2015

Fingerprint

Fish Oils
Cardiovascular Diseases
Lipids
Eicosapentaenoic Acid
Docosahexaenoic Acids
Coronary Artery Disease
Therapeutics
Thrombelastography
Ultracentrifugation
Coronary Angiography
Genetic Markers
Platelet Aggregation
Immunoassay
Gas Chromatography
Adenosine Diphosphate
Atherosclerosis
Thrombosis
Collagen
Population

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy. / Franzese, Christopher J.; Bliden, Kevin P.; Gesheff, Martin G.; Pandya, Shachi; Guyer, Kirk E.; Singla, Anand; Tantry, Udaya S.; Toth, Peter P.; Gurbel, Paul A.

In: The American Journal of Cardiology, Vol. 115, No. 9, 01.05.2015, p. 1204-1211.

Research output: Contribution to journalArticle

Franzese, Christopher J. ; Bliden, Kevin P. ; Gesheff, Martin G. ; Pandya, Shachi ; Guyer, Kirk E. ; Singla, Anand ; Tantry, Udaya S. ; Toth, Peter P. ; Gurbel, Paul A. / Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy. In: The American Journal of Cardiology. 2015 ; Vol. 115, No. 9. pp. 1204-1211.
@article{86c710a7e4c4461faaf7eca3234e7958,
title = "Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy",
abstract = "Fish oil supplementation (FOS) is known to have cardiovascular benefits. However, the effects of FOS on thrombosis are incompletely understood. We sought to determine if the use of FOS is associated with lower indices of atherothrombotic risk in patients with suspected coronary artery disease (sCAD). This is a subgroup analysis of consecutive patients with sCAD (n = 600) enrolled in the Multi-Analyte, Thrombogenic, and Genetic Markers of Atherosclerosis study. Patients on FOS were compared with patients not on FOS. Lipid profile was determined by vertical density gradient ultracentrifugation (n = 520), eicosapentaenoic acid + docosahexaenoic acid was measured by gas chromatography (n = 437), and AtherOx testing was performed by immunoassay (n = 343). Thromboelastography (n = 419), ADP- and collagen-induced platelet aggregation (n = 137), and urinary 11-dehydrothromboxane B2 levels (n = 259) were performed immediately before elective coronary angiography. In the total population, FOS was associated with higher eicosapentaenoic acid + docosahexaenoic acid content (p 2 levels regardless of lipid-lowering therapy (p",
author = "Franzese, {Christopher J.} and Bliden, {Kevin P.} and Gesheff, {Martin G.} and Shachi Pandya and Guyer, {Kirk E.} and Anand Singla and Tantry, {Udaya S.} and Toth, {Peter P.} and Gurbel, {Paul A.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.amjcard.2015.02.002",
language = "English (US)",
volume = "115",
pages = "1204--1211",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy

AU - Franzese, Christopher J.

AU - Bliden, Kevin P.

AU - Gesheff, Martin G.

AU - Pandya, Shachi

AU - Guyer, Kirk E.

AU - Singla, Anand

AU - Tantry, Udaya S.

AU - Toth, Peter P.

AU - Gurbel, Paul A.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Fish oil supplementation (FOS) is known to have cardiovascular benefits. However, the effects of FOS on thrombosis are incompletely understood. We sought to determine if the use of FOS is associated with lower indices of atherothrombotic risk in patients with suspected coronary artery disease (sCAD). This is a subgroup analysis of consecutive patients with sCAD (n = 600) enrolled in the Multi-Analyte, Thrombogenic, and Genetic Markers of Atherosclerosis study. Patients on FOS were compared with patients not on FOS. Lipid profile was determined by vertical density gradient ultracentrifugation (n = 520), eicosapentaenoic acid + docosahexaenoic acid was measured by gas chromatography (n = 437), and AtherOx testing was performed by immunoassay (n = 343). Thromboelastography (n = 419), ADP- and collagen-induced platelet aggregation (n = 137), and urinary 11-dehydrothromboxane B2 levels (n = 259) were performed immediately before elective coronary angiography. In the total population, FOS was associated with higher eicosapentaenoic acid + docosahexaenoic acid content (p 2 levels regardless of lipid-lowering therapy (p

AB - Fish oil supplementation (FOS) is known to have cardiovascular benefits. However, the effects of FOS on thrombosis are incompletely understood. We sought to determine if the use of FOS is associated with lower indices of atherothrombotic risk in patients with suspected coronary artery disease (sCAD). This is a subgroup analysis of consecutive patients with sCAD (n = 600) enrolled in the Multi-Analyte, Thrombogenic, and Genetic Markers of Atherosclerosis study. Patients on FOS were compared with patients not on FOS. Lipid profile was determined by vertical density gradient ultracentrifugation (n = 520), eicosapentaenoic acid + docosahexaenoic acid was measured by gas chromatography (n = 437), and AtherOx testing was performed by immunoassay (n = 343). Thromboelastography (n = 419), ADP- and collagen-induced platelet aggregation (n = 137), and urinary 11-dehydrothromboxane B2 levels (n = 259) were performed immediately before elective coronary angiography. In the total population, FOS was associated with higher eicosapentaenoic acid + docosahexaenoic acid content (p 2 levels regardless of lipid-lowering therapy (p

UR - http://www.scopus.com/inward/record.url?scp=84927571473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927571473&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2015.02.002

DO - 10.1016/j.amjcard.2015.02.002

M3 - Article

C2 - 25759102

AN - SCOPUS:84927571473

VL - 115

SP - 1204

EP - 1211

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 9

ER -